基本信息
浏览量:7
职业迁徙
个人简介
Yiyun Huang, PhD
Professor of Radiology and Biomedical Imaging; Co-Director of Yale PET Center & Director of Chemistry
Research Summary
The main focus of Dr. Henry Huang's research is the development of new and improved Positron Emission Tomography (PET) radioligands. PET ligand development is a process that involves the interplays of chemistry, biology, pharmacology and pharmacokinetics, and it requires a good understanding of all these scientific disciplines. Over the years Dr. Huang has been involved in the development of new or improved PET radioligands for the dopamine, serotonin, glutamate and acetylcholine receptors and transporters in the brain. Development of PET radioligands includes the following stages: 1. design and synthesis of candidate ligands; 2. in vitro pharmacological experiments to determine binding affinities and selectivity. 3. design and execution of biological and pharmacological experiments in live animals including rodents and non-human primates to evaluate the ligands’ in vivo pharmacology and pharmacokinetics such as distribution, binding selectivity and specificity, metabolism, clearance, and blood and brain kinetics; 4. determination of dosimetry and toxicology; 5. clinical trials to determine the ligands’ suitability for applications in humans to image targeted receptors, proteins, or enzymes. PET imaging technique can be used to determine the concentrations of CNS receptors and transporters in discrete brain regions under normal conditions. It can also be used to probe the changes in the densities of certain receptors and transporters in diseases. Coupled with pharmacological manipulation or stimulation, PET imaging is capable of probing the abnormality in the neurotransmission system functions under diseased conditions.
Extensive Research Description
The main focus of Dr. Henry Huang's research is the development of new and improved Positron Emission Tomography (PET) radioligands. PET ligand development is a process that involves the interplays of chemistry, biology, pharmacology and pharmacokinetics, and it requires a good understanding of all these scientific disciplines. Over the years Dr. Huang has been involved in the development of new or improved PET radioligands for the dopamine, serotonin, glutamate and acetylcholine receptors and transporters in the brain. Development of PET radioligands includes the following stages: 1. design and synthesis of candidate ligands; 2. in vitro pharmacological experiments to determine binding affinities and selectivity. 3. design and execution of biological and pharmacological experiments in live animals including rodents and non-human primates to evaluate the ligands’ in vivo pharmacology and pharmacokinetics such as distribution, binding selectivity and specificity, metabolism, clearance, and blood and brain kinetics; 4. determination of dosimetry and toxicology; 5. clinical trials to determine the ligands’ suitability for applications in humans to image targeted receptors, proteins, or enzymes. PET imaging technique can be used to determine the concentrations of CNS receptors and transporters in discrete brain regions under normal conditions. It can also be used to probe the changes in the densities of certain receptors and transporters in diseases. Coupled with pharmacological manipulation or stimulation, PET imaging is capable of probing the abnormality in the neurotransmission system functions under diseased conditions. Further applications include determination of the receptor occupancy by marketed or experimental drugs and monitoring the outcome of drug treatment for diseases. In all these applications the key is the availability of an appropriate PET radioligand for a specific receptor, transporter, or enzyme. Therefore, development of PET radioligands is a critical component of PET imaging and will continue to be the major part of Dr. Huang's research. His current interest is the development of ligands for targets in the CNS encompassing many of the neurotransmission systems.
Professor of Radiology and Biomedical Imaging; Co-Director of Yale PET Center & Director of Chemistry
Research Summary
The main focus of Dr. Henry Huang's research is the development of new and improved Positron Emission Tomography (PET) radioligands. PET ligand development is a process that involves the interplays of chemistry, biology, pharmacology and pharmacokinetics, and it requires a good understanding of all these scientific disciplines. Over the years Dr. Huang has been involved in the development of new or improved PET radioligands for the dopamine, serotonin, glutamate and acetylcholine receptors and transporters in the brain. Development of PET radioligands includes the following stages: 1. design and synthesis of candidate ligands; 2. in vitro pharmacological experiments to determine binding affinities and selectivity. 3. design and execution of biological and pharmacological experiments in live animals including rodents and non-human primates to evaluate the ligands’ in vivo pharmacology and pharmacokinetics such as distribution, binding selectivity and specificity, metabolism, clearance, and blood and brain kinetics; 4. determination of dosimetry and toxicology; 5. clinical trials to determine the ligands’ suitability for applications in humans to image targeted receptors, proteins, or enzymes. PET imaging technique can be used to determine the concentrations of CNS receptors and transporters in discrete brain regions under normal conditions. It can also be used to probe the changes in the densities of certain receptors and transporters in diseases. Coupled with pharmacological manipulation or stimulation, PET imaging is capable of probing the abnormality in the neurotransmission system functions under diseased conditions.
Extensive Research Description
The main focus of Dr. Henry Huang's research is the development of new and improved Positron Emission Tomography (PET) radioligands. PET ligand development is a process that involves the interplays of chemistry, biology, pharmacology and pharmacokinetics, and it requires a good understanding of all these scientific disciplines. Over the years Dr. Huang has been involved in the development of new or improved PET radioligands for the dopamine, serotonin, glutamate and acetylcholine receptors and transporters in the brain. Development of PET radioligands includes the following stages: 1. design and synthesis of candidate ligands; 2. in vitro pharmacological experiments to determine binding affinities and selectivity. 3. design and execution of biological and pharmacological experiments in live animals including rodents and non-human primates to evaluate the ligands’ in vivo pharmacology and pharmacokinetics such as distribution, binding selectivity and specificity, metabolism, clearance, and blood and brain kinetics; 4. determination of dosimetry and toxicology; 5. clinical trials to determine the ligands’ suitability for applications in humans to image targeted receptors, proteins, or enzymes. PET imaging technique can be used to determine the concentrations of CNS receptors and transporters in discrete brain regions under normal conditions. It can also be used to probe the changes in the densities of certain receptors and transporters in diseases. Coupled with pharmacological manipulation or stimulation, PET imaging is capable of probing the abnormality in the neurotransmission system functions under diseased conditions. Further applications include determination of the receptor occupancy by marketed or experimental drugs and monitoring the outcome of drug treatment for diseases. In all these applications the key is the availability of an appropriate PET radioligand for a specific receptor, transporter, or enzyme. Therefore, development of PET radioligands is a critical component of PET imaging and will continue to be the major part of Dr. Huang's research. His current interest is the development of ligands for targets in the CNS encompassing many of the neurotransmission systems.
研究兴趣
论文共 549 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Lindsey R Drake, Yanjun Wu, Mika Naganawa, Ruth Asch, Chao Zheng, Soheila Najafzadeh, Richard Pracitto, Marcel Lindemann, Songye Li, Jim Ropchan, David Labaree, Paul R Emery,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2024)
Jason A. Silva-Rudberg,Elaheh Salardini,Ryan S. O'Dell,Ming-Kai Chen,Jocelyn Ra, Jamie K. Georgelos,Mackenzie R. Morehouse,Kaitlyn P. Melino, Pradeep Parma,Takuya Toyonaga,Nabeel B. Nabulsi,Yiyun Huang,
Yanghong Yang,Mika Naganawa, Nora Hernadenz, Neil Nguyen,Nabeel Nabulsi,Yiyun Huang,Richard Carson,David Matuskey,Elan Louis
NEUROLOGYno. 17 (2023)
引用0浏览0引用
0
0
Biological Psychiatryno. 9 (2023): S326-S326
NeuroImage. Clinical (2023): 103457-103457
引用0浏览0WOS引用
0
0
Biological Psychiatryno. 9 (2023): S317-S318
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn